{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Glutathione",
    "query": {
      "intervention": "Oral Glutathione"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 42,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Glutathione&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T02:14:30.155Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04090138",
      "title": "Setria Performance Blend Supplementation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Setria performance blend",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "30 Years",
        "sex": "MALE",
        "summary": "20 Years to 30 Years · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2019-11-30",
      "completion_date": "2020-11-01",
      "has_results": false,
      "last_update_posted_date": "2021-04-20",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04090138"
    },
    {
      "nct_id": "NCT03020719",
      "title": "The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Oral Glutathione",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-06-14",
      "completion_date": "2018-12-12",
      "has_results": true,
      "last_update_posted_date": "2020-01-09",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 18,
      "location_summary": "Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 15 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03020719"
    },
    {
      "nct_id": "NCT03168711",
      "title": "Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Inosine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 48,
      "start_date": "2017-10-01",
      "completion_date": "2020-01-07",
      "has_results": true,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 3,
      "location_summary": "Fort Lauderdale, Florida • Boston, Massachusetts • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03168711"
    },
    {
      "nct_id": "NCT04265534",
      "title": "KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Non-squamous Non-small-cell Lung Cancer",
        "Non-Squamous Non-Small Cell Neoplasm of Lung",
        "KEAP1 Gene Mutation",
        "NRF2 Gene Mutation",
        "NFE2L2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Telaglenastat",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Folic acid 400 -1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin B12 1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dexamethasone 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-07-24",
      "completion_date": "2022-02-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04265534"
    },
    {
      "nct_id": "NCT01422486",
      "title": "Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "ezatiostat hydrochloride (Telintra®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telik",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2011-10",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2013-11-25",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 5,
      "location_summary": "Maywood, Illinois • Springfield, Illinois • Bethesda, Maryland + 2 more",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422486"
    },
    {
      "nct_id": "NCT02616484",
      "title": "Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pyruvate Dehydrogenase Complex Deficiency"
      ],
      "interventions": [
        {
          "name": "Dichloroacetate (DCA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Genotype",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "Saol Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 34,
      "start_date": "2020-07-14",
      "completion_date": "2025-08-27",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 10,
      "location_summary": "Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616484"
    },
    {
      "nct_id": "NCT01962363",
      "title": "EPI-743 in Friedreich's Ataxia Point Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "EPI-743",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2013-10",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-06-29",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962363"
    },
    {
      "nct_id": "NCT06620523",
      "title": "Prevent Cardiac Surgery Associated AKI Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Failure",
        "Coronary Artery Disease",
        "Surgery",
        "Surgery-Complications"
      ],
      "interventions": [
        {
          "name": "CoQ10 1200 mg orally with Glutathione 1000 mg orally",
          "type": "DRUG"
        },
        {
          "name": "Group B: Placebo CoQ10 orally and Placebo Glutathione orally",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "George Washington University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 242,
      "start_date": "2024-07-18",
      "completion_date": "2028-06-17",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06620523"
    },
    {
      "nct_id": "NCT01044277",
      "title": "Oral Glutathione Supplementation on the Levels of Blood Glutathione",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Adults"
      ],
      "interventions": [
        {
          "name": "Glutathione supplementation",
          "type": "DRUG"
        },
        {
          "name": "Gluthathione peroxidases",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "30 Years to 79 Years"
      },
      "enrollment_count": 61,
      "start_date": "2010-02",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2022-09-06",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01044277"
    },
    {
      "nct_id": "NCT04419025",
      "title": "Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID",
        "Sars-CoV2",
        "SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere",
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cambridge Health Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2020-09-23",
      "completion_date": "2021-05-14",
      "has_results": false,
      "last_update_posted_date": "2021-05-28",
      "last_synced_at": "2026-09-29T02:14:30.155Z",
      "location_count": 4,
      "location_summary": "Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "Everett",
          "state": "Massachusetts"
        },
        {
          "city": "Somerville",
          "state": "Massachusetts"
        },
        {
          "city": "Somerville",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04419025"
    }
  ]
}